Valor diagnóstico de la procalcitonina, la interleucina 8, la interleucina 6 y la proteína C reactiva en la detección de bacteriemia y fungemia en pacientes con cáncer

Aznar-Oroval, Eduardo; Sánchez-Yepes, Marina; Lorente-Alegre, Pablo; Juan-Gadea, Mari Carmen San; Ortiz-Muñoz, Blanca; Pérez-Ballestero, Pilar; Picón-Roig, Isabel; Maiquez-Richart, J

doi:10.1016/j.eimc.2009.08.001

Cited by 17 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our work, all patients showed a favorable outcome. There are few studies that analyzed together the kinetics of CRP, PCT and IL-6 in pediatric patients with fever and neutropenia [19] and to our knowledge this is the first study that describes MR-proADM kinetics with the rest of them. Our results confirmed that the kinetics of these four biomarkers is similar in patients with cancer compared to non-oncological patients.…”

Section: Biomarker Levels and Kineticsmentioning

confidence: 99%

Biomarkers and Fever in Children with Cancer: Kinetics and Levels According to Final Diagnosis

et al. 2021

View full text Add to dashboard Cite

We investigated the kinetics of CRP, PCT, IL-6 and MR-proADM in a cohort of consecutive febrile patients with cancer in order to test the hypothesis that higher plasma concentrations and the absence of a rapid decrease in peak values would be associated with disease severity. (1) Method: A prospective descriptive and analytical study of patients with cancer and fever (≤18 years of age) at a University Hospital was carried out between January 2018 and December 2019. Information collected: sex, age, diagnosis, date and symptoms at diagnosis and medical history. The episodes were classified into three groups: bacterial infection, non-bacterial infection and systemic inflammatory response syndrome (SIRS). (2) Results: One hundred and thirty-four episodes were included. Bacterial infection criteria were met in 38 episodes. Biomarkers were measured at four different points: baseline, at 12–24 h, at 25–48 h and at 49–72 h. All the biomarkers evaluated decreased after the peak level was reached. IL-6 and MR-proADM showed a trend towards higher levels in the SIRS group although this rise was statistically significant only for IL-6 (p < 0.005). Bacterial infections more frequently presented values of PCT above the cut-off point (>0.5 ng/mL) at 12–24 h. (3) Conclusion: In our experience, IL-6 kinetics is faster than PCT kinetics and both are faster than CRP in patients with fever and cancer who present a good outcome. Patients with a good evolution show a rapid increase and decrease of PCT and particularly of IL-6 levels.

show abstract

Section: Biomarker Levels and Kineticsmentioning

confidence: 99%

Biomarkers and Fever in Children with Cancer: Kinetics and Levels According to Final Diagnosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…14 The results of Aznar-Oroval's group's study on 79 patients with neoplasia, published in September 2010, are also in line with previous findings. 15 Several studies have also focused on testing the effectiveness of measuring PCT values in helping the differential diagnosis of fever in cancer patients with neutropenia as a consequence of both a hematologic disease and/or a chemotherapy. 9,[16][17][18] Jimeno et al reported 104 consecutive febrile episodes in neutropenic patients.…”

Section: Use Of Procalcitonin In the Differential Diagnosis Of Fever ...mentioning

confidence: 99%

Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study

et al. 2013

View full text Add to dashboard Cite

Fever often occurs in cancer patients and the possibility of having a reliable marker for the differential etiological diagnosis is desirable. The aim of this study was to investigate the eligibility of the use of procalcitonin (PCT) in hemato-oncological patients for the differential diagnosis of fever. We prospectively enrolled 98 cancer patients and divided them into two groups: those with active disease and those with non-active disease. Procalcitonin was dosed at Time 0 (recruitment) and at the onset of fever. On enrollment, PCT values were 0.1 ng/mL in 83% patients with active disease, and lower than 0.5 ng/mL in 23%, which is usually considered not suggestive of bacterial infection. Four percent of patients had values over 0.5 ng/mL and these were mainly patients with neuroendocrine tumors or affiliates. On enrollment, there were also no statistically significant differences in PCT values between the two groups of patients. This showed that active cancer is unable by itself to change PCT levels. In the active disease group, 21 episodes of fever due to bacterial infection were registered, and in all of them an increase in PCT values was observed. This demonstrates the ability of PCT to detect an infection-induced fever in cancer patients. Procalcitonin concentrations are not significantly altered by active neoplastic disease. On the contrary, in the course of fever due to a bacterial infection, PCT values increase and can, therefore, be considered a useful tool in the differential diagnosis between infection-induced fever and drug-related or tumor associated-fever. Procalcitonin may be a useful marker of bacterial infection even in cancer patients.

show abstract

“…No obstante, actualmente numerosos trabajos defienden la utilidad de la PCT: para mejorar el diagnó stico de IB en los SUH 47,48 , como criterio para la exclusió n de bacteriemia en la neumonía comunitaria 49 , y en el paciente neoplá sico con fiebre y neutropenia 50 . Así mismo, se ha propuesto la determinació n de la PCT en pacientes con fiebre y procesos inflamatorios cró nicos, como criterio en la diferenciació n entre la actividad de la enfermedad de base y un proceso infeccioso intercurrente 51 .…”

Section: Expectativas De Una Aplicació N Prá Cticaunclassified

Biomarcadores y sospecha de infección en los servicios de urgencias

et al. 2012

View full text Add to dashboard Cite

Valor diagnóstico de la procalcitonina, la interleucina 8, la interleucina 6 y la proteína C reactiva en la detección de bacteriemia y fungemia en pacientes con cáncer

Cited by 17 publications

References 28 publications

Biomarkers and Fever in Children with Cancer: Kinetics and Levels According to Final Diagnosis

Biomarkers and Fever in Children with Cancer: Kinetics and Levels According to Final Diagnosis

Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study

Biomarcadores y sospecha de infección en los servicios de urgencias

Contact Info

Product

Resources

About